Current therapeutic approaches include anti-inflammatory[8] and antioxidant treatments,[9] along with the use of mineralocorticoid receptor antagonists, endothelin receptor antagonists, and vitamin D receptor activators.[10] Epigenetics is increasingly acknowledged as crucial in understanding the pathogenesis and progression of DN.[11] With advancements in medical technology, significant progress has been made in diagnosing and treating DN. The gene discussed is NR3C2; the disease is liver dysplastic nodule.